1. Scrip

Andromeda's DiaPep277 : beating a path to type 1 diabetes?

Andromeda Biotech has released top-line results for its lead product, DiaPep277, that suggest it could prove an effective immunotherapeutic product for patients with newly diagnosed type 1 diabetes.

Andromeda Biotech has released top-line results for its lead product, DiaPep277, that suggest it could prove an effective immunotherapeutic product for patients with newly diagnosed type 1 diabetes.

The promising data follow a number of setbacks in this field, and revive hopes that it will be possible to...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Alimentary/Metabolic

More from Therapeutic Category

Novartis Secures Approval For First Malaria Therapy for Babies

 
• By Kevin Grogan

Coartem Baby to be rolled out in eight African countries in the autumn.

Could Apogee Rival Regeneron/Sanofi, Lilly After Phase II Eczema Data Win?

 
• By Manas Mishra

Apogee Therapeutics reports data from Phase II APEX trial of its long-acting antibody against atopic dermatitis, showing similar efficacy to Regeneron/Sanofi’s Dupixent and Eli Lilly’s Ebglyss.

Cogent Peaks With Bezaclastinib SUMMIT Results

 
• By Alaric DeArment

The biotech announced positive topline results from the Phase II SUMMIT study in non-advanced systemic mastocytosis, with data for advanced SM and GIST expected later this year.